Table 5 Chemotherapeutic trials in breast cancer patients metastatic to the brain
Chemotherapy | N | Clinical study type | Objective response rate (%) | Progression-free survival (months) | Overall survival (months) | Reference |
|---|---|---|---|---|---|---|
Cyclophosphamide, 5FU, methotrexate* | 22 | Prospective | 59 (37-80) | NR | 6.3 (0.5-20.8) | Boogerd et coll. (1992)[26] |
Cisplatine etoposide | 56 | Prospective | 38 (NR) | 4,3 (0-71,8) | 7.8 (0-71.8) | Franciosi et coll. (1999)[28] |
Temozolomide capecitabine | 24 | Phase I | 18 (NR) | 3 (0.8-17.5) | NR | Rivera et coll. (2006)[29] |
HD Methotrexate | 32 (29 BC) | Retrospective | 28 (NR) | NR | 4.6 (0.7-31.2) | Lassman et coll. (2006)[13] |
Capecitabine | 7 | Retrospective | 28 (NR) | NR | NR | Ekenel et coll. (2007)[22] |
Lapatinib** | 39 | Phase II | 2,6 (0,2-26) | 3 (2.3-3.7) | NR | Lin et coll. (2008)[34] |
Lapatinib** | 242 | Phase II | 6 (3.6-10.2) | 2.4 (1.87-2.79) | 6.37 (5.49-8.25) | Lin et col. (2009)[35] |
Carmustin methotrexate (present study) | 50 | Retrospective | 23 (12 - 37.3) | 4.2 (2.8-5.3) | 6.9 (4.2-10.7) |